Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH

Inclusion Criteria: • Histologically documented diagnosis of CD38 (cluster of differentiation 38) positive PTCL-NOS, AITL and other nodal lymphomas of TFH cell origin as defined in the 2017 edition of the World Health Organization (WHO) classification. Patients with only bone marrow involvement are eligible. Note: Only patients with a centrally assessed percentage of CD38 positive tumor cells ≥ 5% in the relapse biopsy, or in the more recent biopsy in the case of refractory patients, will be considered eligible for protocol study treatment. * Age 18-70 years * Relapsed or refractory to one previous lines of treatment (autologous transplantation as a consolidation to the first line of therapy should not be considered a second line) * Eastern Cooperative Oncology Group (ECOG) performance status (PS) \< 2 * At least one site of measurable nodal disease at baseline ≥ 2.0 cm in the longest transverse diameter as determined by CT scan (MRI is allowed only if CT scan cannot be performed). Note: Patients with only bone marrow involvement are eligible * Adequate hematological counts defined as follows: * Absolute Neutrophil count (ANC) \> 1.0 x 109/L unless due to bone marrow involvement by lymphoma * Platelet count \> 100.000/mm3 unless due to bone marrow involvement by lymphoma * Adequate renal function defined as follows: \- Creatinine clearance ≥ 40 mL/min (Cockcroft-Gault formula) * Adequate hepatic function per local laboratory reference range as follows: * Asparta…